

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application of:	Storer <i>et al</i>	Confirmation No.:	2201
Serial No.:	10/608,907	Art Unit:	1623
Filed:	June 27, 2003	Examiner:	T. McIntosh III
For:	MODIFIED 2' AND 3' NUCLEOSIDE PRODRUGS FOR TREATING FLAVIVIRIDAE INFECTIONS	Attorney Docket No:	11874-055-999
		(CAM:	417451-999055)
			IDX 1018

**TERMINAL DISCLAIMER**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Petitioner Idenix Pharmaceuticals, Inc. is an assignee of less than the entire right, title and interest in and to the above identified application by virtue of an assignment which was recorded on February 25, 2003 at reel 013780 frame 0832.

Petitioner hereby disclaims the terminal part of any patent granted on the above identified application which would extend beyond the expiration date of the patent granted on U.S. Patent Application No. 11/005,445, filed December 6, 2004 and hereby agrees that any patent so granted on the above identified application shall be enforceable only for and during such period that the legal title to said patent shall be the same as the legal title to the patent granted on U.S. Patent Application No. 11/005,445.

Petitioner further agrees that this agreement is to run with any patent granted on the above identified application and is to be binding upon the grantee, its successors, and assigns.

Petitioner does not disclaim any terminal part of any patent granted on the above-identified application prior to the expiration date of the full statutory term of the patent granted on U.S. Patent Application No. 11/005,445 in the event that said patent later expires for failure to pay a maintenance fee, is held unenforceable, is found invalid, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. 1.321(a), has all claims canceled by a reexamination certificate, or is otherwise terminated prior to the expiration of its full statutory term, except for the separation of legal title stated above.

Petitioner hereby confirms that he has reviewed the assignment and, to the best of his knowledge and belief, title is in the assignee seeking to take action in this matter and that he is empowered to act on behalf of Idenix Pharmaceuticals, Inc.

Petitioner hereby declares that all statements made herein of his own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Signed this 25<sup>th</sup> day of June, 2008.

Idenix Pharmaceuticals, Inc.

By: 

Name: John F. Weldenbruch, Esq.

Position: EXECUTIVE VICE PRESIDENT  
AND GENERAL COUNSEL

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application of:	Storer <i>et al</i>	Confirmation No.:	2201
Serial No.:	10/608,907	Art Unit:	1623
Filed:	June 27, 2003	Examiner:	T. McIntosh III
For:	MODIFIED 2' AND 3' NUCLEOSIDE PRODRUGS FOR TREATING FLAVIVIRIDAE INFECTIONS	Attorney Docket No:	11874-055-999
		(CAM:	417451-999055)
			IDX 1018

**TERMINAL DISCLAIMER**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Petitioner Frédéric Foubert represents that he holds the position of Directeur du Service du Transfert de Technologies of Centre National De La Recherche Scientifique, the assignee of less than the entire right, title and interest in and to the above identified application by virtue of an assignment which was recorded on February 25, 2003 at reel 013781 frame 0026.

Petitioner hereby disclaims the terminal part of any patent granted on the above identified application which would extend beyond the expiration date of the patent granted on U.S. Patent Application No. 11/005,445, filed December 6, 2004, and hereby agrees that any patent so granted on the above identified application shall be enforceable only for and during such period that the legal title to said patent shall be the same as the legal title to the patent granted on U.S. Patent Application No. 11/005,445.

Petitioner further agrees that this agreement is to run with any patent granted on the above identified application and is to be binding upon the grantee, its successors, and assigns.

Petitioner does not disclaim any terminal part of any patent granted on the above-identified application prior to the expiration date of the full statutory term of the patent granted on U.S. Patent Application No. 11/005,445 in the event that said patent later expires for failure to pay a maintenance fee, is held unenforceable, is found invalid, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. 1.321(a), has all claims canceled by a reexamination certificate, or is otherwise terminated prior to the expiration of its full statutory term, except for

the separation of legal title stated above.

Petitioner hereby confirms that he has reviewed the assignment and, to the best of his knowledge and belief, title is in the assignee seeking to take action in this matter and that he is empowered to act on behalf of Centre National De La Recherche Scientifique.

Petitioner hereby declares that all statements made herein of his own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Signed this 9 day of July, 2008.

1 Directeur de la Politique Industrielle

Marc J. LEDOUX

Direction de la Politique Industrielle  
Le Secrétaire Général

Patrice SOULLIE

Centre National De La Recherche Scientifique

Directeur du Service du Transfert de  
Technologies

By: \_\_\_\_\_

Name: Frédéric Poubert

Position: Directeur du Service du Transfert de Technologies

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application of:	Storer <i>et al</i>	Confirmation No.:	2201
Serial No.:	10/608,907	Art Unit:	1623
Filed:	June 27, 2003	Examiner:	T. McIntosh III
For:	MODIFIED 2' AND 3' NUCLEOSIDE PRODRUGS FOR TREATING FLAVIVIRIDAE INFECTIONS	Attorney Docket No:	11874-055-999 (CAM: 417451-999055) IDX 1018

**TERMINAL DISCLAIMER**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Universita Degli Studi Di Cagliari is an assignee of less than the entire right, title and interest in and to the above identified application by virtue of an assignment from Paolo LaColla, a copy of which is attached hereto.

Petitioner hereby disclaims the terminal part of any patent granted on the above identified application which would extend beyond the expiration date of the patent granted on U.S. Patent Application No. 11/005,445, filed December 6, 2004 and hereby agrees that any patent so granted on the above identified application shall be enforceable only for and during such period that the legal title to said patent shall be the same as the legal title to the patent granted on U.S. Patent Application No. 11/005,445.

Petitioner further agrees that this agreement is to run with any patent granted on the above identified application and is to be binding upon the grantee, its successors, and assigns.

Petitioner does not disclaim any terminal part of any patent granted on the above-identified application prior to the expiration date of the full statutory term of the patent granted on U.S. Patent Application No. 11/005,445 in the event that said patent later expires for failure to pay a maintenance fee, is held unenforceable, is found invalid, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. 1.321(a), has all claims canceled by a reexamination certificate, or is otherwise terminated prior to the expiration of its full statutory term, except for the separation of legal title stated above.

Petitioner hereby confirms that he has reviewed the assignment and, to the best of his knowledge and belief, title is in the assignee seeking to take action in this matter and that he is empowered to act on behalf of Università Degli Studi Di Cagliari.

Petitioner hereby declares that all statements made herein of his own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Signed this \_\_\_\_ day of \_\_\_\_\_, 2008.

18 LUG. 2008

Università Degli Studi Di Cagliari


By: 

Name: Adolfo Lai

Position: Prorettore

Certifico io Ufficiale Rogante Sostituto  
dell'Università degli Studi di Cagliari  
che la firma, apposta in mia presenza dal  
Prof. Adolfo Lai nato a Ottana il  
26.07.1943, Pro Rettore dell'Università  
di Cagliari e della cui identità personale  
sono certo, è autentica

L'Ufficiale Rogante Sostituto  
Dr. Achille Umberto Puzos



## ASSIGNMENT

WHEREAS, WE, WHEREAS, WE, JEAN-PIERRE SOMMADOSSI, PAOLO LA COLLA, RICHARD STORER, AND GILLES GOSSELIN, have invented certain improvements in "Modified 2' and 3' -Nucleoside Prodrugs for Treating *Flaviviridae* Infections" for which We have executed U.S. Provisional application No. 60/392,351, filed June 28, 2002; U.S. Provisional application No. 60/392,350, filed June 28, 2002; U.S. Provisional Application No. 60/466,194, filed April 28, 2003; U.S. Provisional application no. 60/470,949 filed May 14, 2003; and U.S. Non-provisional filing on June 27, 2003 and;

WHEREAS, UNIVERSITA DEGLI STUDI DI CAGLIARI, with a mailing address of Cittadella Universitaria SS 554, Km. 4.500, 09042 MONSERRATO (CA), Italy desires to purchase the interest of Paolo LaColla;

NOW, THEREFORE, in consideration of the sum of Five Dollars (\$5.00) and other good and valuable consideration paid by UNIVERSITA DEGLI STUDI DI CAGLIARI, the receipt and sufficiency of which are hereby acknowledged, I, PAOLO LA COLLA, have sold, assigned, transferred and conveyed and by these presents do hereby sell, assign, transfer and convey unto UNIVERSITA DEGLI STUDI DI CAGLIARI, in and for any foreign counterpart thereof or any other application, the entire right, title and interest in and to said provisional application, in and to the invention therein set forth and in and to any patent which may issue on said application any foreign counterpart thereof or any other application or any application, reissue, renewal, division, continuation or continuation-in-part thereof; and I hereby bind myself, my heirs, legal representatives, administrators and assigns properly to execute without further consideration, any and all applications, petitions, oaths and assignments or other papers and instruments which may be necessary in order to carry into full force and effect the sale, assignment, transfer and conveyance hereby made or intended to be made.

IN WITNESS WHEREOF, I have hereunto set my hand and seal this 18 day of

Aug, 2003.

Paolo La Colla  
PAOLO LA COLLA

Jane Oswecki  
Witness JANE OSWECKI

Cynthia B. Gayre  
Cynthia B Gayre  
Notary Public  
My Comm Expires Sept 17, 2006